慶應義塾研究者情報データベース

経歴 【 表示 ／ 非表示 】

経歴 【 表示 ／ 非表示 】

• 2018年04月

  -

  2018年09月

  株式会社 SKY CREATE 海浜総合薬局　薬剤師

• 2018年10月

  -

  2019年11月

  シドニー大学薬学部 訪問研究員

• 2019年12月

  -

  2021年12月

  アドバンス株式会社　さくら調剤薬局　薬剤師

• 2021年12月

  -

  2024年04月

  株式会社 SKY CREATE 海浜総合薬局　管理薬剤師

• 2024年05月

  -

  2025年12月

  慶應義塾大学薬学部　実務実習事前学習（実習）補助

全件表示 >>

学歴 【 表示 ／ 非表示 】

学歴 【 表示 ／ 非表示 】

• 2008年04月

  -

  2014年03月

  崇城大学

  大学, 卒業

• 2014年04月

  -

  2018年03月

  崇城大学

  大学院, 修了, 博士

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia

  Mizukami Y., Takahashi M., Suzuki K., Duan S., Ikegami S., Muraishi T., Satake N., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

  Journal of Infection and Chemotherapy 32 （ 1 ）  2026年01月

  ISSN  1341321X

  　概要を見る

  Introduction: Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC<inf>i</inf>), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC<inf>i</inf>-based PK/PD analysis in the lung epithelial lining fluid (ELF). Methods: In vitro pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing Klebsiella pneumoniae strains. In vivo PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC<inf>i</inf>-based PK/PD analysis was conducted. Results: In vitro, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12–4.30 log<inf>10</inf> CFU/lung, while the combination therapy reduced bacterial counts by −5.93 to −0.234 log<inf>10</inf> CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC<inf>i</inf> (T > MIC<inf>i</inf>) was highly correlated with bacterial reduction. The target T > MIC<inf>i</inf> for maximal effect was estimated to be 29.3 %. Conclusions: These findings support the utility of MIC<inf>i</inf>-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.

  • Access to Document (DOI)

• Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

  Kawasaki A., Shintani R., Takao R., Nakazawa Y., Mihara T., Ikegami S., Shimada S., Matsumoto Y., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

  Medical Mycology 63 （ 10 ）  2025年10月

  ISSN  13693786

  　概要を見る

  Background Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited. Objectives This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole. Results Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group. Conclusions ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.

  • Access to Document (DOI)

• 医療用一般用共用医薬品 (仮称) の創設提言に対する薬剤師の認知および見解に関する実態把握調査.

  （医療薬学）  51 （ 4 ） 196 - 202 2025年04月

  研究論文（学術雑誌）, 筆頭著者, 査読有り

  • Access to Document (DOI)

• SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database

  Takada K., Taguchi K., Samura M., Igarashi Y., Okamoto Y., Enoki Y., Tanikawa K., Matsumoto K.

  Journal of Infection and Chemotherapy 31 （ 1 ）  2025年01月

  ISSN  1341321X

  　概要を見る

  Background: The association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines and myocarditis/pericarditis in the Japanese population has not been systematically investigated. This study was aimed at clarifying the association between SARS-CoV-2 mRNA vaccines (BNT162b2 and mRNA-1273) and myocarditis/pericarditis as well as influencing factors by using the Japanese Adverse Drug Event Report database. Methods: Reporting odds ratios (RORs) and 95 % confidence intervals (95 % CIs) for the association between the vaccines and myocarditis/pericarditis were calculated using data from the database (April 2004–December 2023). Age, sex, onset time, and outcomes in symptomatic patients were evaluated. Results: The total number of reports was 880,999 (myocarditis: 1846; pericarditis: 761). The adverse events associated with the vaccines included myocarditis (919 cases) and pericarditis (321 cases), with the ROR [95 % CIs] being significant for both (myocarditis: 30.51 [27.82–33.45], pericarditis: 21.99 [19.03–25.40]). Furthermore, the ROR [95 % CIs] of BNT162b2 and mRNA-1273 were 15.64 [14.15–17.28] and 54.23 [48.13–61.10], respectively, for myocarditis, and 15.78 [13.52–18.42] and 27.03 [21.58–33.87], respectively, for pericarditis. Furthermore, most cases were ≤30 years or male. The period from vaccination to onset was ≤8 days, corresponding to early failure type based on analysis using the Weibull distribution. Outcomes were recovery or remission for most cases; however, they were severe or caused death in some cases. Conclusion: In the Japanese population, SARS-CoV-2 mRNA vaccination was significantly associated with the onset of myocarditis/pericarditis. The influencing factors included age of ≤30 years and male. Furthermore, although most adverse events occurred early after vaccination, overall outcomes were good.

  • Access to Document (DOI)

• Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice

  Hara R., Taguchi K., Ogino H., Okamoto Y., Enoki Y., Kizu J., Hori S., Matsumoto K.

  Journal of Pharmaceutical Health Care and Sciences 10 （ 1 ）  2024年12月

  　概要を見る

  Background: Fluoroquinolone (FQ) antimicrobials have antipyretic effects during the treatment of bacterial infections; however, it is not clear whether these are due to their antimicrobial activities or their hypothermic effects. In this study, we investigated the hypothermic effects of FQ antimicrobials (ciprofloxacin [CPFX], gatifloxacin [GFLX], and levofloxacin [LVFX]) on fever by evaluating rectal body temperature changes in a mouse model of non-bacterial fever. Methods: CPFX, GFLX, and LVFX were administered intraperitoneally to non-bacterial fever model mice induced by yeast. Rectal body temperature was measured up to 180 min after administration. Results: A decrease in rectal body temperature of up to 1.2 °C for CPFX, 3.4 °C for GFLX, and 1.0 °C for LVFX was observed. The decrease in temperature was induced by an increase in the plasma concentration of FQ antimicrobials, suggesting that they are responsible for the temperature reduction. Focusing on glucocorticoids, one thermoregulation mechanism, we investigated the substances responsible for the reduction in rectal body temperature induced by FQ antimicrobials. Aminoglutethimide (an inhibitor of glucocorticoid production) were premedicated, followed by intraperitoneal administration of GFLX in the yeast-induced fever mouse model, resulting in attenuated GFLX-induced hypothermic effects. Conclusions: These results suggest that certain antipyretic effects of CPFX, GFPX, and LVFX during fever may contribute to their hypothermic effects; certain mechanisms are glucocorticoid-mediated.

  • Access to Document (DOI)

所属学協会 【 表示 ／ 非表示 】

所属学協会 【 表示 ／ 非表示 】

• 日本医療薬学会, 

  2025年05月

  -

  継続中

• 日本口腔ケア学会, 

  2025年03月

  -

  継続中

• 日本老年薬学会, 

  2025年03月

  -

  継続中